|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cai T, Nesi G, Tinacci G, Giubilei G,
Gavazzi A, Mondaini N, Zini E and Bartoletti R: Clinical importance
of lymph node density in predicting outcome of prostate cancer
patients. J Surg Res. 167:267–272. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bader P, Burkhard FC, Markwalder R and
Studer UE: Disease progression and survival of patients with
positive lymph nodes after radical prostatectomy. Is there a chance
of cure? J Urol. 169:849–854. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weckermann D, Dorn R, Trefz M, Wagner T,
Wawroschek F and Harzmann R: Sentinel lymph node dissection for
prostate cancer: Experience with more than 1,000 patients. J Urol.
177:916–920. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gervasi LA, Mata J, Easley JD, Wilbanks
JH, Seale-Hawkins C, Carlton CE Jr and Scardino PT: Prognostic
significance of lymph nodal metastases in prostate cancer. J Urol.
142:332–336. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng L, Zincke H, Blute ML, Bergstralh
EJ, Scherer B and Bostwick DG: Risk of prostate carcinoma death in
patients with lymph node metastasis. Cancer. 91:66–73. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zwergel U, Lehmann J, Wullich B, Schreier
U, Remberger K, Zwergel T and Stoeckle M: Lymph node positive
prostate cancer: Long-term survival data after radical
prostatectomy. J Urol. 171:1128–1131. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fleischmann A, Rocha C, Schobinger S,
Seiler R, Wiese B and Thalmann GN: Androgen receptors are
differentially expressed in Gleason patterns of prostate cancer and
down-regulated in matched lymph node metastases. Prostate.
71:453–460. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ko K, Jeong IG, Choi WS, Lim JH, Suh JH,
Ku JH, Park Y, Moon KC, Kim HH, Kim CS and Kwak C: Effect of
Gleason scores of lymph node metastases on prognosis of patients
with prostate cancer. Int J Clin Exp Pathol. 7:6141–6148.
2014.PubMed/NCBI
|
|
10
|
Tomlins SA, Rhodes DR, Perner S,
Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J,
Kuefer R, et al: Recurrent fusion of TMPRSS2 and ETS transcription
factor genes in prostate cancer. Science. 310:644–648. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Urbinati G, Ali HM, Rousseau Q, Chapuis H,
Desmaële D, Couvreur P and Massaad-Massade L: Antineoplastic
effects of siRNA against TMPRSS2-ERG junction oncogene in prostate
cancer. PLoS One. 10:e01252772015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Urbinati G, de Waziers I, Slamiç M,
Foussignière T, Ali HM, Desmaële D, Couvreur P and Massaad-Massade
L: Knocking down TMPRSS2-ERG fusion oncogene by siRNA could be an
alternative treatment to flutamide. Mol Ther Nucleic Acids.
5:e3012016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shao L, Tekedereli I, Wang J, Yuca E,
Tsang S, Sood A, Lopez-Berestein G, Ozpolat B and Ittmann M: Highly
specific targeting of the TMPRSS2/ERG fusion gene using liposomal
nanovectors. Clin Cancer Res. 18:6648–6657. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang X, Qiao Y, Asangani IA, Ateeq B,
Poliakov A, Cieślik M, Pitchiaya S, Chakravarthi BVSK, Cao X, Jing
X, et al: Development of peptidomimetic inhibitors of the ERG gene
fusion product in prostate cancer. Cancer Cell. 31(532–548):
e72017.
|
|
15
|
Furusato B, Tan SH, Young D, Dobi A, Sun
C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, et
al: ERG oncoprotein expression in prostate cancer: Clonal
progression of ERG-positive tumor cells and potential for ERG-based
stratification. Prostate Cancer Prostatic Dis. 13:228–237. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mehra R, Tomlins SA, Shen R, Nadeem O,
Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM and
Shah RB: Comprehensive assessment of TMPRSS2 and ETS family gene
aberrations in clinically localized prostate cancer. Mod Pathol.
20:538–544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Minner S, Gärtner M, Freudenthaler F,
Bauer M, Kluth M, Salomon G, Heinzer H, Graefen M, Bokemeyer C,
Simon R, et al: Marked heterogeneity of ERG expression in large
primary prostate cancers. Mod Pathol. 26:106–116. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsourlakis MC, Stender A, Quaas A, Kluth
M, Wittmer C, Haese A, Graefen M, Steurer S, Simon R, Korbel J, et
al: Heterogeneity of ERG expression in prostate cancer: A large
section mapping study of entire prostatectomy specimens from 125
patients. BMC Cancer. 16:6412016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Minner S, Enodien M, Sirma H, Luebke AM,
Krohn A, Mayer PS, Simon R, Tennstedt P, Müller J, Scholz L, et al:
ERG status is unrelated to PSA recurrence in radically operated
prostate cancer in the absence of antihormonal therapy. Clin Cancer
Res. 17:5878–5888. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fleischmann A, Saramäki OR, Zlobec I,
Rotzer D, Genitsch V, Seiler R, Visakorpi T and Thalmann GN:
Prevalence and prognostic significance of TMPRSS2-ERG gene fusion
in lymph node positive prostate cancers. Prostate. 74:1647–1654.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wise AM, Stamey TA, McNeal JE and Clayton
JL: Morphologic and clinical significance of multifocal prostate
cancers in radical prostatectomy specimens. Urology. 60:264–269.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Clement T, Swars H, Boerner N, Klose KJ,
John H, Warnecke M and Weilemann LS: Venous occlusive disease of
the liver-a rare pregnancy complication. Internist (Berl).
31:297–300. 1990.(In German). PubMed/NCBI
|
|
23
|
Barry M, Perner S, Demichelis F and Rubin
MA: TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer:
Clinical and biologic implications. Urology. 70:630–633. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Svensson MA, LaFargue CJ, MacDonald TY,
Pflueger D, Kitabayashi N, Santa-Cruz AM, Garsha KE, Sathyanarayana
UG, Riley JP, Yun CS, et al: Testing mutual exclusivity of ETS
rearranged prostate cancer. Lab Invest. 91:404–412. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang S, Pavlovitz B, Tull J, Wang Y, Deng
FM and Fuller C: Detection of TMPRSS2 gene deletions and
translocations in carcinoma, intraepithelial neoplasia, and normal
epithelium of the prostate by direct fluorescence in situ
hybridization. Diagn Mol Pathol. 19:151–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Font-Tello A, Juanpere N, de Muga S,
Lorenzo M, Lorente JA, Fumado L, Serrano L, Serrano S, Lloreta J
and Hernández S: Association of ERG and TMPRSS2-ERG with grade,
stage, and prognosis of prostate cancer is dependent on their
expression levels. Prostate. 75:1216–1226. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hagen RM, Adamo P, Karamat S, Oxley J,
Aning JJ, Gillatt D, Persad R, Ladomery MR and Rhodes A:
Quantitative analysis of ERG expression and its splice isoforms in
formalin-fixed, paraffin-embedded prostate cancer samples:
Association with seminal vesicle invasion and biochemical
recurrence. Am J Clin Pathol. 142:533–540. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hägglöf C, Hammarsten P, Strömvall K,
Egevad L, Josefsson A, Stattin P, Granfors T and Bergh A:
TMPRSS2-ERG expression predicts prostate cancer survival and
associates with stromal biomarkers. PLoS One. 9:e868242014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Klein EA, Falzarano SM, Maddala T,
Cherbavaz D, Novotny WF, Millward C and Magi-Galluzzi C: Use of
TMPRSS2-ERG gene rearrangement and quantitative ERG expression to
predict clinical recurrence after radical prostatectomy. J Clin
Oncol. 29 Suppl:S362011. View Article : Google Scholar
|
|
30
|
Terry S, Nicolaiew N, Basset V, Semprez F,
Soyeux P, Maillé P, Vacherot F, Ploussard G, Londoño-Vallejo A, de
la Taille A and Allory Y: Clinical value of ERG, TFF3, and SPINK1
for molecular subtyping of prostate cancer. Cancer. 121:1422–1430.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guo CC, Wang Y, Xiao L, Troncoso P and
Czerniak BA: The relationship of TMPRSS2-ERG gene fusion between
primary and metastatic prostate cancers. Hum Pathol. 43:644–649.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Perner S, Svensson MA, Hossain RR, Day JR,
Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R,
Demichelis F, et al: ERG rearrangement metastasis patterns in
locally advanced prostate cancer. Urology. 75:762–767. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tomlins SA, Laxman B, Dhanasekaran SM,
Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, et
al: Distinct classes of chromosomal rearrangements create oncogenic
ETS gene fusions in prostate cancer. Nature. 448:595–599. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carver BS, Tran J, Chen Z, Carracedo-Perez
A, Alimonti A, Nardella C, Gopalan A, Scardino PT, Cordon-Cardo C,
Gerald W and Pandolfi PP: ETS rearrangements and prostate cancer
initiation. Nature. 457(E1): discussion E2-E3. 2009.PubMed/NCBI
|
